Observational studyEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real-life study.
Observational study in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does Patient-Reported Olfactory Improvement Correlate with Quality of Life and Polyp Size Reduction in Patients with CRSwNP Treated with Dupilumab?Medicines (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic rhinosinusitis with nasal polyps (CRSwNP) is associated with morbidity and impairment in quality of life. Lately, new biological drugs have been developed and approved for its treatment. Dupilumab was the first to be approved but long-term real-world results are still limited.
methodsThis is a real-life, multicenter observational study assessing the effectiveness of dupilumab in patients with CRSwNP with a follow-up from 3 to 24 months. We focused on nasal polyps score (NPS), quality of life (SNOT-22), olfactory function and blood eosinophils trend. Moreover, results were stratified by previous surgery, comorbidities, and blood eosinophils and IgE levels at baseline.
resultsWe observed a significant decrease in NPS and SNOT-22 from baseline to all the follow-up sessions. Olfaction improved over time and a significant difference was observed between baseline and 12 and 18 months. At 12 months follow-up, NPS of patients who had undergone surgery was lower than NPS of naïve patients (p =.012). Surgery did not influence SNOT-22 or improvement of smell. Comorbidities did not affect the outcomes. Blood eosinophils increased from baseline, reaching a peak at 3 months and gradually decreasing to a value similar to baseline at 18 months. The level of blood eosinophils and total IgE at baseline did not influence the effect of the drug on NPS at 12 months. No major adverse events were observed.
conclusionDupilumab was proven to be effective in terms of reduction of dimension of nasal polyps, improvement of quality of life and olfaction and no major adverse events were observed.
Indexed as
Identifiers
40652138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.